Ayman J. Oweida

Has grant

Associate Professor

Université de Sherbrooke
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Ayman J. Oweida is an assistant professor at Université de Sherbrooke in Canada. His research primarily focuses on the interplay between immunotherapy and radiotherapy in solid tumors, particularly in head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer. He has published articles examining the roles of various signaling pathways and immune cell interactions in the response to radiation therapy.

Recent Grants

Grant: Close

Targeting immunosuppressive chemokines for enhanced response to radiotherapy in squamous cell cancers

Open Date: 2021-09-01

Close Date: 2023-08-31

Grant: Close

Radiotherapy for stimulation of anti-tumor immunity

Open Date: 2021-03-23

Close Date:

Grant: Close

Anti-Tumor Immunity by Radiotherapy

Open Date: 2021-02-01

Close Date: 2026-01-31

Grant: Close

Development of an immune imaging method to accurately determine the immune status of tumors

Open Date: 2020-04-01

Close Date: 2021-03-31

Grant: Close

Compréhension des mécanismes impliqués dans la réponse aux traitements anti-cancéreux combinant immunothérapie et radiothérapie

Open Date: 2020-04-01

Close Date: 2024-03-31

Articles (10)

Toll-like receptors (TLRs) are indispensable for the activation, maintenance and halting of immune responses. TLRs can mediate inflammation by recognizing molecular patterns in microbes (pathogen-associated molecular patterns: PAMPs) and endogenous ligands (danger-associated molecular patterns: DAMPs) released by injured or dead cells. For this reason, TLR ligands have attracted much attention in recent years in many cancer vaccines, alone or in combination with immunotherapy, chemotherapy and radiotherapy (RT). TLRs have been shown to play controversial roles in cancer, depending on various factors that can mediate tumor progression or apoptosis. Several TLR agonists have reached clinical trials and are being evaluated in combination with standard of care therapies, including RT. Despite their prolific and central role in mediating immune responses, the role of TLRs in cancer, particularly in response to radiation, remains poorly understood. Radiation is recognized as either a direct stimulant of TLR pathways, or indirectly through the damage it causes to target cells that subsequently activate TLRs. These effects can mediate pro-tumoral and anti-tumoral effects depending on various factors such as radiation dose and fractionation, as well as host genomic features. In this review, we examine how TLR signaling affects tumor response to RT, and we provide a framework for the design of TLR-based therapies with RT.

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (3)

Brisa Peña

Assistant Professor

University of Denver

UNITED STATES
View details

Adam Mueller

Assistant Professor

University of Pittsburgh

UNITED STATES
View details

Jennifer Boer

MONASH UNIVERSITY

AUSTRALIA
View details